Oncolytic virus therapy mobilizes tumor-resident CD4+ bystander T cells to restore systemic anti-microbial immunity [ATAC-seq]

ATAC-seq library was prepared using Hyperactive ATAC-seq Library Prep Kit for Illumina (Vazyme, TD711) to study SM CD4+ T cells in lung and spleen when undergoing OV-BYTE treatment. Here, we further demonstrate that OV-BYTE delivered dual defense against tumorigenesis and pathogen infections in pre-clinical models. This study gives a epigenetic profiles of SM CD4+ T cells in lung and spleen with administration of OV-BYTE treatment. Overall design: Congenic CD45.1+ SM CD4+ T cells were adoptively transferred into naive C57BL/6 recipients (CD45.2+), which were then infected with LCMV Armstrong and engrafted with MC38 cells on Day 60 post infection. On days 7-12 after tumor engraftment, recipients were intratumorally administered with PBS, NDV-WT or NDV-GP. On day 15 post tumor engraftment, SM CD4+ T cells in tumor and spleen were sorted by FACS and analyzed using ATAC-seq.